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Beta blockersAbstract Background: Beta blockers are very commonly used as antihypertensive medications in
young active individuals. This class has been accused of erectile dysfunction in patients taking them.
Problems with erectile function can raise a concern in the treatment of hypertension and may
inﬂuence the choice of treatment regimens and decisions to discontinue drugs.
Aim: The aim was to assess the effect of different beta blockers: nebivolol, atenolol, bisoprolol, and
carvedilol on the penile arterial duplex velocities in hypertensive males.
Methods and results: 108 non-smoking, non-diabetic, recently diagnosed hypertensive men, other-
wise healthy, participated in the study. The patients were divided into four groups: Group 1 (24
patients) who were taking 5 mg of nebivolol, Group 2 (28 patients) who took 100 mg of atenolol,
Group 3 (29 patients) who were taking 10 mg of bisoprolol, and Group 4 (27 patients) who were on
25 mg of carvedilol. The penile vascular velocities were measured before treatment and after a treat-
ment phase of eight to twelve weeks of beta blocker antihypertensive treatment. We obtained a sta-
tistically signiﬁcant diminish of the stimulated PSV with atenolol (P= 0.03), bisoprolol (P= 0.05),
and carvedilol (P= 0.02), while, with nebivolol the PSV did not show a signiﬁcant change
(P= 0.7). There was also a signiﬁcant decrease of the stimulated EDV with nebivolol (0.04) with
no change with the other beta blockers.
Conclusion: Nebivolol is a unique member of the beta blocker family showing neutral effects on the
penile vascular velocities as compared to other beta blockers in hypertensive males.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Erectile dysfunction (ED), the persistent inability to achieve
and/or maintain an erection sufﬁcient for satisfactory sexual
activity (1) is a condition of increasing prevalence worldwide
which has been estimated to affect 150 million individuals
and is supposed to impact up to 50% of men between the ages
of 40 and 70 (2). ED and hypertension are common conditions
Fig. 1 Cavernosal artery by grayscale bi-dimensional ultrasound.
Fig. 2 Cavernosal artery by grayscale bi-dimensional ultrasound.
750 S.M. Botros et al.that possibly share pathophysiologic pathways. Compared to
the general population, hypertensive patients have a higher
prevalence of ED (3,4). However, an important point has been
raised as to whether the higher prevalence of ED in those
patients is the result of hypertension per se, or of antihyperten-
sive treatment, or as a combination of both. ED has an impor-
tant impact on the quality of life and this leads to patients’
non-compliance to antihypertensive therapy whenever it is
believed that their ED is related to their antihypertensive drug
therapy. Keene et al. reported drug-related erectile dysfunction
in approximately 25% of cases, being mostly readily reversible
when the drug is stopped, or a suitable alternative is given (5).
The complaint of erectile dysfunction is frequent in patients
with cardiovascular disease especially when treated with beta-
blockers. Issues of cause and effect are confused because car-
diovascular disease ‘per se’ may cause erectile dysfunction, as
there appears to be a higher rate of sexual dysfunction in
untreated men with cardiovascular disease compared with
men of similar age (6).
Beta blockers are a drug class of wide heterogeneity in terms
of selectivity to adrenergic receptors, intrinsic sympathetic activ-
ity and vasoactive effects. Some beta blockers, such as nebivolol,
carvedilol, labetalol and celiprolol, possess variable degrees of
vasodilatory properties. Since vasoconstriction may contribute
to vasculogenic sexual dysfunction through reduced blood sup-
ply, it could be hypothesized that vasodilatory beta blockers
may diverge in clinically meaningful ways from traditional beta
blockers on their effects in sexual function. However, this
assumption seems to be only partially correct, since observa-
tional and clinical data suggest that carvedilol shares the negative
effects of traditional beta blockers on sexual function (7), while
nebivolol might be the only exception in this class of antihyper-
tensive drugs regarding the effects on erectile function (8,9).
The negative effects of beta blockers on sexual function have
been recently debated (10,11). Two studies reported that erectile
dysfunction induced by treatment with beta blockers is primarily
due to knowledge of side effects and similarly occurs with pla-
cebo (12,13); therefore, beta blocker-induced erectile dysfunction
seems to be perceived and not real. On the other hand, there are
three carefully designed, randomized crossover studies, con-
ducted byFogari (14,15), aiming to evaluate speciﬁcally the effect
of antihypertensive treatment in erectile function. These studies
provide strong evidence for a negative effect of beta blockers
on erectile function, since beta blockers were worse than placebo,
which in turn was worse than renin-angiotensin system inhibi-
tors. Although a placebo effect, at least in some patients, cannot
be entirely excluded, available data indicate that a negative effect
of beta blockers on sexual function cannot be negated (10).
1.1. Aim of the study
The aim was to assess the effect of different beta blockers:
nebivolol, atenolol, bisoprolol, and carvedilol on the penile
arterial duplex velocities in hypertensive males.
2. Patients and methods
2.1. Patients
108 nonsmoking, non-diabetic, recently diagnosed hyperten-
sive men, otherwise healthy, participated in the study, whichwas approved by the Ethics Committee of the University of
Ain Shams. All patients gave an informed consent before par-
ticipating in the study.
The patients underwent a thorough history including the
International Index of Erectile Function (IIEF-5) criteria.
They all had an echocardiogram (ECG), and laboratory test-
ing including fasting blood sugar and 2 h post prandial to
exclude those with Diabetes Mellitus.
All patients underwent an exercise treadmill test to exclude
the presence of ischemic coronary artery disease.
The patients were then divided into four groups: Group 1
(24 patients) who were taking 5 mg of nebivolol, Group 2
(28 patients) who took 100 mg of atenolol, Group 3 (29
patients) who were taking 10 mg of bisoprolol, and Group 4
(27 patients) who were on 25 mg of carvedilol.
Fig. 3 Cavernosal artery ﬂow by color pulsed duplex.
Fig. 4 Cavernosal artery ﬂow by color pulsed duplex.
Table 1 The demographic, clinical, and echo-cardio-graphic data o
Group 1 nebivolol
(n= 24)
Group 2 atenolol
(n= 28)
Age (years) 42.2 ± 3.4 41.6 ± 4.2
Height (m) 1.67 ± 0.12 1.72 ± 0.18
Weight (kg) 80.2 ± 5.8 82.5 ± 7.2
BMI (kg/m2) 28.2 ± 4.7 27.9 ± 6.5
SBP (mmHg) 153.4 ± 10.3 155.2 ± 9.6
DBP
(mmHg)
95.3 ± 5.1 96.2 ± 6.3
HR (bpm) 88.4 ± 7.5 91.2 ± 8.3
LVEF (%) 62.3 ± 4.2 58.9 ± 6.3
Effect of different beta blockers 751The penile vascular velocities were measured before treat-
ment and after a treatment phase of eight to twelve weeks of
beta blocker antihypertensive treatment. All included patients
were recently diagnosed to have hypertension and had subjec-
tive complaints of erectile dysfunction. They all had baseline
pretreatment post-injection cavernosal artery PSV above
35.1 cm/s and baseline pretreatment post-injection cavernosal
artery EDV below 4.9 cm/s.
2.2. Methods
Penile color pulsed duplex and spectral pulsed duplex:
(Figs. 1–3).
All the duplex examinations were performed with
(ALPINION E-CUBE 9, Seoul, Korea) ultrasound machine
using a 7 MHz linear phased array transducer. Each case
had its pre and post treatment duplex done by the same radi-
ologist to avoid inter-observer variabilities. Doppler angle was
standardized at 59 degrees.
The patients underwent penile duplex twice: the ﬁrst time
was before the start of antihypertensive beta blocker treatment
and the second time was after eight to twelve weeks of beta
blocker antihypertensive treatment. The penile duplex is
detailed as follows: First, ﬂaccid state pre-injection assessment
included using grayscale bi-dimensional ultrasound for mea-
suring bilateral penile cavernosal arteries inner to inner diam-
eters (C.A.Diam. in millimeters, mm) and also included using
color pulsed duplex and spectral pulsed duplex for measuring
bilateral penile cavernosal arteries peak systolic velocities (PSV
in centimeter per second, cm/s). The C.A.Diam and PSV mea-
surements were both taken at mid-dorsum penis on each side
to obtain a mean derived from 2 measurements for each
parameter. Thereafter, following thorough local skin asepsis,
and using an insulin syringe with the less traumatizing slim
short hypodermic needle, the penile circulation was stimulated
by an intra-cavernosal injection of 2 ml of Vasorin (papaverine
manufactured by Memphis pharmaceuticals-2 ml ampoule of
30 mg/ml concentration): 1 ml in each corpus cavernosum at
middle third of dorsum penis while applying a tourniquet at
penile root to be removed 2 min after injection. Then the stim-
ulated peak systolic velocities (PSV in centimeter per second,
cm/s) and end diastolic velocities (EDV in centimeter per sec-
ond, cm/s) as well as the cavernosal arteries inner to inner
diameters (C.A.Diam. in millimeters, mm) were all measured
4 times on each side during the following 20 minutes at 5f different groups.
Group 3 bisoprolol
(n= 29)
Group 4 carvedilol
(n= 27)
P value
44.1 ± 2.3 43.5 ± 1.8 0.3
1.73 ± 0.2 1.69 ± 0.09 0.2
81.4 ± 8.4 78.1 ± 7.1 0.7
27.6 ± 5.3 27.3 ± 6.2 0.8
151.9 ± 8.7 156.3 ± 9.5 0.6
93.5 ± 4.6 92.9 ± 5.3 0.8
90.6 ± 6.9 86.4 ± 9.1 0.7
64.1 ± 4.6 61.7 ± 5.8 0.4
Table 2 The penile duplex parameters, before and after initiation of beta-blocker antihypertensive therapy in different groups.
Penile duplex
parameters
Group 1 nebivolol
(n= 24)
Group 2 atenolol
(n= 28)
Group 3 bisoprolol
(n= 29)
Group 4 carvedilol
(n= 27)
Before treatment
Flacc.C.A.Diam. (mm) 0.32 ± 0.01 0.35 ± 0.02 0.33 ± 0.01 0.34 ± 0.02
Flacc.PSV (cm/s) 11.3 ± 1 13.1 ± 2 12.7 ± 1.8 12.4 ± 1.5
Stim.C.A.Diam. (mm) 0.53 ± 0.02 0.58 ± 0.04 0. 56 ± 0.03 0.57 ± 0.03
Stim.PSV (cm/s) 38.3 ± 2.1 39.6 ± 2.7 39.4 ± 2.6 38.8 ± 2.5
Stim.EDV (cm/s) 3.2 ± 1.4 3.0 ± 1.1 2.9 ± 1.2 3.1 ± 1.3
After treatment
Flacc.C.A.Diam. (mm) 0.32 ± 0.01 0.35 ± 0.02 0.33 ± 0.01 0.34 ± 0.02
Flacc.PSV (cm/s) 11.7 ± 1.3 12.3 ± 1.4 12.5 ± 1.6 12.2 ± 1.2
Stim.C.A.Diam. (mm) 0.56 ± 0.03 0.53 ± 0.03 0.55 ± 0.03 0.56 ± 0.03
Stim.PSV (cm/s) 38.8 ± 2.8 34.5 ± 1.6 34.6 ± 2.3 33.9 ± 2.2
Stim.EDV (cm/s) 2.4 ± 1.1 2.8 ± 1.8 2.8 ± 1.4 3.0 ± 1.5
Table 3 Penile stimulated PSV and stimulated EDV in patients before and after initiation of beta-blocker antihypertensive therapy in
different groups.
Stim.PSV (cm/s) before
treatment
Stim.PSV (cm/s) after
treatment
P
value
Stim.EDV (cm/s) before
treatment
Stim.EDV (cm/s) after
treatment
P
value
Group 1
nebivolol
38.3 ± 2.1 38.8 ± 2.8 0.7 3.2 ± 1.4 2.4 ± 1.1 0.04
Group 2
atenolol
39.6 ± 2.7 34.5 ± 1.6 0.03 3.0 ± 1.1 2.8 ± 1.8 0.7
Group 3
bisoprolol
39.4 ± 2.6 34.6 ± 2.3 0.05 2.9 ± 1.2 2.8 ± 1.4 0.8
Group 4
carvedilol
38.8 ± 2.5 33.9 ± 2.2 0.02 3.1 ± 1.3 3.0 ± 1.5 0.1
752 S.M. Botros et al.minute intervals to obtain a mean derived from 8 measure-
ments for each parameter (see Fig. 4 and Table 1).
2.3. Statistical analysis of the data
We used the Student’s paired t-test for analyzing the paramet-
ric data and the w2 test for analyzing the categorical data.
P< 0.05 was considered statistically signiﬁcant.Fig. 5 Cavernosal artery ﬂow by spectral pulsed duplex before
initiation of treatment by atenolol.3. Results
When comparing the four different beta blockers on the penile
duplex parameters, we obtained a statistically signiﬁcant
diminish of the PSV with atenolol (P= 0.03), bisoprolol
(P= 0.05), and carvedilol (P= 0.02), while, with nebivolol
the PSV showed an insigniﬁcant increase (P= 0.7) (Table 2
and Fig. 9).Fig. 6 Cavernosal artery ﬂow by spectral pulsed duplex after
treatment by atenolol.
Fig. 7 Cavernosal artery ﬂow by spectral pulsed duplex before
initiation of treatment by carvedilol.
Fig. 8 Cavernosal artery ﬂow by spectral pulsed duplex after
treatment by carvedilol.
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Fig. 9 Penile stimulated PSV in patients before and after initiatio
Effect of different beta blockers 753There was also a signiﬁcant decrease of the EDV with nebi-
volol (0.04) and no signiﬁcant change was seen with the other
beta blockers (Table 3, and Figs. 5–8 and 10).
4. Discussion
Beta blockers are still the most commonly used anti-hyperten-
sive medications in several countries including our own; Egypt.
They show beneﬁcial control especially in young active
hypertensives.
Beta-blockers have been reported to be responsible for erec-
tile dysfunction in many (1–3), but not all studies (4). It has
been suggested that this may be because of the change in bal-
ance between alpha and beta sympathetic inﬂuence, resulting
in insufﬁcient antagonism of alpha-1 vasoconstriction (5).
Many of these studies were biased by relatively heterogeneous
group of patients having organic or psychogenic (or both) pre-
disposing factors in addition to drug related causes.
Problems with erectile function can raise a concern in the
treatment of hypertension and may inﬂuence the choice of
treatment regimens and decisions to discontinue drugs.
We compared the effects of four beta blocking agents on
penile ﬂow in hypertensive men using color Doppler ultra-
sound method. We tried to minimize these complex factors
and investigated relatively young healthy men having solely
hypertension as a risk factor of vascular disease and we used
a highly selected patient sample due to the importance of
excluding any other factors that could affect the outcome.
The newer nitric oxide releasing beta blocker nebivolol was
shown not to affect the quality of life in relation to erectile dys-
function in comparison with losartan (16) or when switching
patients from other beta blockers to nebivolol (9).
However, most of the data that were previously presented,
were obtained through subjective questionnaires and not by
objective evidence as we sought out to do. We obtained ﬂaccid
and stimulated penile vascular velocities in these rather healthy
males before and after giving them different beta blockers
thereby trying to eliminate any psychological factor that can
inﬂuence the outcome after beta blockers as seen by Silvestri
et al. 2003 that patients who did not know that they were tak-
ing atenolol had a lower incidence than those who knew that
they were taking it and knew its possible side effects (16).and aer therapy PSV (cm/s)
n of beta-blocker antihypertensive therapy in different groups.
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Fig. 10 Penile stimulated EDV in patients before and after initiation of beta-blocker antihypertensive therapy in different groups.
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obliterating this confusing factor.
We obtained a statistically signiﬁcant diminish of the stim-
ulated PSV with atenolol (P= 0.03), bisoprolol (P= 0.05),
and carvedilol (P= 0.02), while, with nebivolol the stimulated
PSV did not show a signiﬁcant change (P= 0.7).
There was also a signiﬁcant decrease of the stimulated EDV
with nebivolol (0.04) with no change with the other beta
blockers.
This could explain the so commonly seen neutral or even
beneﬁcial effects of nebivolol on the erectile dysfunction in
males.
5. Conclusion
Nebivolol is a unique member of the beta blocker family show-
ing neutral effects on the penile vascular velocities as compared
to other beta blockers in hypertensive males.
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